Copyright
©The Author(s) 2022.
World J Clin Cases. Aug 16, 2022; 10(23): 8170-8185
Published online Aug 16, 2022. doi: 10.12998/wjcc.v10.i23.8170
Published online Aug 16, 2022. doi: 10.12998/wjcc.v10.i23.8170
Figure 1 Flow diagram, randomization, and treatment assignment.
COVID-19: Coronavirus disease 2019; ICU: Intensive care unit.
Figure 2 Kaplan Meier survival analysis among the study groups showing no significant survival benefit in favor of famotidine as added treatment against the control group, P > 0.
05.
Figure 3 Comparison of outcomes among the famotidine treatment group A, and the control group B.
aP < 0.05, bP < 0.01, cP ≤ 0.0001.
- Citation: Mohiuddin Chowdhury ATM, Kamal A, Abbas MKU, Karim MR, Ali MA, Talukder S, Hamidullah Mehedi HM, Hassan H, Shahin AH, Li Y, He S. Role of H2 receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial. World J Clin Cases 2022; 10(23): 8170-8185
- URL: https://www.wjgnet.com/2307-8960/full/v10/i23/8170.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i23.8170